Keeping Track: Submissions Complete For Breakthrough Therapies From Portola And Catalyst; FDA Finally Approves Bridion, Basaglar

 
• By Bridget Silverman

The latest drug development news and highlights from our FDA Performance Tracker.

More from Clinical Trials

More from R&D